Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

AL OWNERSHIP

Check this box if no longer subject	STATEMENT OF CHANGES IN BENEFICE												
to Section 16. Form 4 or Form 5													
obligations may continue. See													

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* INGRAM ROBERT ALEXANDER				2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX]								(Chec	5. Relationship of Reporting Per Check all applicable) X Director			10% O	wner		
(Last)	(Fir	st) (M	Middle) EUTIC	S, INC.	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2022										Office	er (give title v)		Other (below)	specify
ONE MAIN STREET, 10TH FLOOR				03/10/2022															
(Street)	IDGE M	A 0	2142		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line) X	Form Form	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (Z	Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)				Execution D		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			4 and Securi Benefi		ties cially I Following	Form (D) o	vnership I: Direct r Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(
Common Stock 03/18/2					2022			A ⁽¹⁾		5,795 A		\$	3.02 ⁽²⁾	18,397			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)		ion Date,		saction (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) V (A) (D)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amount or Numbe of Title Shares		De Se (In	Price of trivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- 2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022.

/s/ Brent Hatzis-Schoch, 03/18/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.